Recruiting

Tau Imaging

Sponsor:

Mayo Clinic

Code:

NCT02605785

Conditions

Progressive Supranuclear Palsy

Eligibility Criteria

Sex: All

Age: 35+

Healthy Volunteers: Accepted

Interventions

F-18 AV 1451

Study Details

Brief summary:

This study is designed to learn more about overall tau burden in the brain of patients with Progressive Supranuclear Palsy (PSP).

Conditions

Progressive Supranuclear Palsy

Study ID

NCT02605785

Start date

Nov, 2015

Status verified date

Apr, 2026

Completion date

Jan, 2030

Anticipated

Primary completion date

Jan, 2030

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 35+

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Must be over 35 years of age and present with gradual progression of PSP-related symtoms
  • Must have an informant or study partner that can provide independent information of functioning.
  • Must meet criteria for possible or probable Progressive Supranuclear Palsy. To fulfill criteria for possible PSP, subjects must have a gradually progressive disorder with either vertical (upward or downward) supranuclear palsy or both slowing of vertical saccades and prominent postural instability with falls in the first year of disease onset. To fulfill criteria for probable PSP, subjects must have vertical (upward or downward gaze) supranuclear palsy and prominent postural instability with falls in the first year of disease onset.

Exclusion Criteria:

  • Subjects will be excluded if they meet criteria for another neurodegenerative disease (including corticobasal syndrome, frontotemporal dementia, primary progressive aphasia, Alzheimer's disease, multiple system atrophy and Parkinson's disease) or do not have the symptoms necessary to fulfill inclusion criteria for possible PSP.
  • Subjects with concurrent illnesses that could account for their symptoms, such as traumatic brain injury, encephalitis, strokes or developmental syndromes will be excluded.
  • Women that are pregnant or post-partum and breast-feeding will be excluded.
  • Subjects will be excluded from the study if they have any of the following genetic conditions which can increase the chance of cancer: Cowden disease, Lynch syndrome, hypogammaglobulinemia, Wiskott-Aldrich syndrome, and Down's syndrome.
  • Subjects will also be excluded if MRI is contraindicated (metal in head, cardiac pace maker, e.t.c.), if there is severe claustrophobia, if there are conditions that may confound brain imaging studies (e.g. structural abnormalities, including subdural hematoma, intracranial neoplasm or large cortical infarcts), or if they are medically unstable or are on medications that might affect brain structure or metabolism (e.g. chemotherapy).
  • Subjects will also be excluded if they do not have an informant, or do not consent to research.

Study Design

Enrollment

332 participants

Anticipated

Intervention Model

Single group

Primary purpose

Diagnostic

Interventions and Outcome Measures

Arms

experimental: Tau PET Scan, F-18 AV 1451

All subjects will received a Tau PET scan.

Interventions

F-18 AV 1451

Tau PET scan

Primary outcome measure

  • The investigators will be looking at the amount of Tau protein in the brain of patients with PSP. [ Time Frame: 5 years ]

Central Contacts and Locations

Central contacts

Sarah M Boland, CCRP

507-284-3863boland.sarah@mayo.edu

Locations

Mayo Clinic

Recruiting

Rochester, Minnesota, United States, 55905

Contacts

Sarah M Boland, CCRP

507-284-3863boland.sarah@mayo.edu

More Information

Sponsor

Mayo Clinic

Last update posted

May 5, 2026

Last verified

Apr, 2026

Keywords

  • PSP

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Mayo Clinic on 2026-05-05.